Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept [PDF]
Journal of the American Heart AssociationBackground Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology ...
Basil S Lewis +2 more
exaly +8 more sources
Expanding the Patient Pool for Rilonacept [PDF]
JACC: Case ReportsRecurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed ...
Emma St. John, MD +9 more
exaly +6 more sources
A Comprehensive Clinical Evaluation of Rilonacept in the Treatment of Recurrent Pericarditis: A Systematic Review [PDF]
Journal of Inflammation ResearchYue Yu, Jiajing Chen, Zhao Zhao, Moting Qian, Yufei Zhang, Chunlai Ma Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, People’s Republic of ChinaCorrespondence: Chunlai Ma, Email chunlaima@126.comObjective: Recurrent ...
Yu Y +5 more
exaly +6 more sources
Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS) [PDF]
Journal of Inflammation Research, 2010 Justin Gillespie, Rebeccah Mathews, Michael F McDermottNIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Institute of Molecular Medicine (LIMM), St.
Michael F McDermott
exaly +10 more sources
Comprehensive Clinical Analysis of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: A Systematic Review [PDF]
Journal of Multidisciplinary HealthcareTian Zhang,1 Yue Yu,2 Jiajing Chen,2 Zhao Zhao,2 Moting Qian,2 Yufei Zhang,2 Chunlai Ma,2 Feng Chang3 1Institute of Science and Technology, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China; 2Department of Pharmacy, Huashan ...
Zhang T +7 more
exaly +6 more sources
Inhibition of interleukin‐1 with rilonacept is not effective in cold urticaria—Results of a randomized, placebo‐controlled study [PDF]
Clinical and Translational Allergy, 2023 Background Cold urticaria (ColdU) is characterized by pruritic wheals following exposure of the skin to cold. Many patients show insufficient response to antihistamines, the first line treatment.
Hanna Bonnekoh
exaly +4 more sources
Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY [PDF]
Journal of the American Heart Association, 2022 Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY (rilonacept inhibition of interleukin‐1 alpha and beta for recurrent pericarditis: a pivotal ...
Michelle Lim-Watson +2 more
exaly +4 more sources
Recurrent Sterile Pleuropericarditis After Withdrawal of Renal Transplant Immunosuppression in Anuric ESRD: A Case of Suspected IL-1–Mediated Autoinflammation [PDF]
Case Reports in RheumatologyRecurrent pericarditis and serositis pose a significant diagnostic challenge in patients with end-stage renal disease (ESRD) and a history of extensive immunosuppression.
Evelien van Gelderen +2 more
doaj +3 more sources
Assessing the Impact of Rilonacept on Lipid Profiles in Patients With Recurrent Pericarditis [PDF]
JACC: AdvancesAnkit Agrawal, Muhammad Majid
exaly +6 more sources
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis [PDF]
Current Cardiology Reports, 2022 We reviewed the contemporary literature and clinical trials to discuss the applications of the interleukin-1 (IL-1) inhibitor rilonacept to treat pericarditis, with regards to pathophysiology, pharmacology, efficacy, and safety.Rilonacept is an emerging novel agent for treating recurrent pericarditis, with phase II and III clinical trials recently ...
Tom Kai Ming Wang
exaly +3 more sources